Logo image of STRO

SUTRO BIOPHARMA INC (STRO) Stock Analyst Ratings

USA - Nasdaq - NASDAQ:STRO - US8693671021 - Common Stock

0.8433 USD
0 (-0.39%)
Last: 11/21/2025, 8:01:26 PM
0.8265 USD
-0.02 (-1.99%)
After Hours: 11/21/2025, 8:01:26 PM
Buy % Consensus

75

ChartMill assigns a Buy % Consensus number of 75% to STRO. The Buy consensus is the weighted average rating of the current analysts ratings.

Analysts have set a mean price target forecast of 2.74. This target is 224.84% above the current price.
STRO was analyzed by 16 analysts. The buy percentage consensus is at 75. So analysts seem to be have mildly positive about STRO.
In the previous month the buy percentage consensus was at a similar level.
STRO was analyzed by 16 analysts, which is quite many. So the average rating should be quite meaningful.
STRO Historical Analyst RatingsSTRO Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -84 -76 -68 -60 -52 -44 -36 -28 -20 -12 -4 5 10 15

Price Target & Forecast

Price Low Median Mean High 0.840.812.042.745.25 - -4.19% 141.91% 224.84% 522.55%
STRO Current Analyst RatingSTRO Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6
Up and Down Grades
Date Firm Action Rating
2025-08-12 Wells Fargo Maintains Equal-Weight -> Equal-Weight
2025-06-16 Piper Sandler Upgrade Neutral -> Overweight
2025-05-19 B of A Securities Maintains Underperform -> Underperform
2025-04-29 HC Wainwright & Co. Reiterate Neutral -> Neutral
2025-03-17 HC Wainwright & Co. Downgrade Buy -> Neutral
2025-03-14 Citizens Capital Markets Downgrade Market Outperform -> Market Perform
2025-03-14 Wedbush Downgrade Outperform -> Neutral
2025-03-14 B of A Securities Downgrade Buy -> Underperform
2024-12-11 JMP Securities Reiterate Market Outperform -> Market Outperform
2024-12-11 Wells Fargo Maintains Equal-Weight -> Equal-Weight
2024-11-18 HC Wainwright & Co. Reiterate Buy -> Buy
2024-10-11 Piper Sandler Reiterate Overweight -> Overweight
2024-10-11 HC Wainwright & Co. Reiterate Buy -> Buy
2024-09-16 JMP Securities Reiterate Market Outperform -> Market Outperform
2024-09-16 HC Wainwright & Co. Reiterate Buy -> Buy
2024-08-16 Truist Securities Maintains Buy -> Buy
2024-08-14 HC Wainwright & Co. Reiterate Buy -> Buy
2024-05-15 Oppenheimer Maintains Outperform -> Outperform
2024-05-14 Wedbush Reiterate Outperform -> Outperform
2024-05-14 HC Wainwright & Co. Reiterate Buy -> Buy
2024-05-08 B of A Securities Initiate Buy
2024-04-03 JMP Securities Reiterate Market Outperform -> Market Outperform
2024-04-03 Oppenheimer Maintains Outperform -> Outperform
2024-04-03 Truist Securities Maintains Buy -> Buy
2024-04-03 Piper Sandler Reiterate Overweight -> Overweight
2024-03-28 Oppenheimer Maintains Outperform -> Outperform
2024-03-27 Oppenheimer Maintains Outperform -> Outperform
2024-03-26 JMP Securities Reiterate Market Outperform -> Market Outperform
2024-03-26 Wedbush Maintains Outperform -> Outperform
2024-03-26 HC Wainwright & Co. Maintains Buy -> Buy

SUTRO BIOPHARMA INC / STRO FAQ

What is the average price target for SUTRO BIOPHARMA INC (STRO) stock?

16 analysts have analysed STRO and the average price target is 2.74 USD. This implies a price increase of 224.84% is expected in the next year compared to the current price of 0.8433.


What is the consensus rating for SUTRO BIOPHARMA INC (STRO) stock?

The consensus rating for SUTRO BIOPHARMA INC (STRO) is 75 / 100 . This indicates that analysts generally have a positive outlook on the stock.


Can you provide the analyst count for SUTRO BIOPHARMA INC stock?

The number of analysts covering SUTRO BIOPHARMA INC (STRO) is 16.